Pacira Pharmaceuticals Announces CFO Transition and Interim Replacement
Company Announcements

Pacira Pharmaceuticals Announces CFO Transition and Interim Replacement

Pacira Pharmaceuticals ( (PCRX) ) has provided an announcement.

Pacira BioSciences, Inc. is set for a leadership transition as Charles A. Reinhart III, the CFO, plans to leave by September 30, 2024, staying on as a consultant for nine more months. Lauren Riker, the company’s Senior VP of Finance, will step up as the interim CFO from October 1. With a decade at Pacira and no direct or familial ties influencing her appointment, Riker will maintain her current salary and bonus structure, adding a $75,000 bonus for her new role, which comes with specific repayable conditions. Her employment terms include various severance and insurance benefits, with additional provisions in the event of a company “change of control.”

See more data about PCRX stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyPacira price target lowered to $17 from $25 at Barclays
TheFlyPacira price target raised to $12 from $11 at Piper Sandler
TipRanks Auto-Generated NewsdeskPacira BioSciences Reports Q3 2024 Earnings and Strategic Developments
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App